Drug and Therapeutics Bulletin 2001;39:49-52; doi:10.1136/dtb.2001.39749
Copyright © 2001 by the BMJ Publishing Group Ltd.
Etanercept and infliximab for rheumatoid arthritis
Relevant BNF section: 10.1.3
▼Etanercept* (Enbrel - Wyeth) and▼infliximab* (Remicade - Schering Plough) belong to a new class of drugs that block the effects of tumour necrosis factor-alpha (TNF-
), a mediator of inflammation. Both are licensed for the treatment of patients with active rheumatoid arthritis who have responded inadequately to disease-modifying antirheumatic drugs (DMARDs). Here, we consider whether etanercept and infliximab offer advantages.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
(2008). Rituximab and {blacktriangledown}abatacept for rheumatoid arthritis. DTB
46: 57-61
[Abstract] [Full Text]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Infections
-
Malignant disease and immunosuppression
-
Haematology (drugs and medicines)
-
Musculoskeletal and joint disorders
-
Oncology
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
